title: Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia.
abstract: OBJECTIVE
  To describe the neuropathological and biochemical findings of the brain examination of a patient enrolled in the AN-1792(QS-21) trial with an initial clinical diagnosis of Alzheimer disease (AD), in whom Lewy body variant was thereafter clinically diagnosed.
  
  
  METHODS
  A case report.
  
  
  METHODS
  University memory clinic. Patient A 74-year-old woman with clinical features of probable AD. Intervention The patient received 2 injections of 225 mug of AN-1792 (beta-amyloid [Abeta]) plus 50 mug of the adjuvant QS-21 at an interval of 4 weeks. The patient was an antibody responder with an IgG anti-AN-1792 antibody titer exceeding 10 000 and an IgM titer exceeding 3500. Maximum serum anti-Abeta titers were reached in 4.7 months. During the 3 following years, while the Mini-Mental State Examination score remained globally stable despite several confusional episodes, she developed clinical features of dementia with Lewy bodies. The patient died 34 months postimmunization. An autopsy was performed.
  
  
  METHODS
  Neuropathological and biochemical examination of the brain using standardized evaluation for tau, beta-amyloid, and synuclein deposits.
  
  
  RESULTS
  Neither neuropathological nor biochemical examinations showed amyloid deposit in the brain of this immunized patient. For tau deposition, Braak stage was IV/VI, and the Western blot analysis score was 9c/10. The neuropathological semiquantitative score for alpha-synuclein aggregation was 4. There was no inflammation. These results were compared with those of an age-matched patient with AD and a control devoid of any neurological disease.
  
  
  CONCLUSIONS
  In this Lewy body variant case, with globally stable functional and cognitive features, Abeta immunization resulted in a significant clearance of amyloid deposits, with remaining tau and synuclein pathological features in the brain. Patients with a Lewy body variant of AD should not be excluded from enrollment in Abeta-immunization trials.
authors.affiliation: Department of Neurology, Resource and Research Memory Center, University Hospital, Lille, France.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Bombois
authors.forename: Claude-Alain
authors.initials: CA
authors.lastname: Maurage
authors.forename: Marie
authors.initials: M
authors.lastname: Gompel
authors.forename: Vincent
authors.initials: V
authors.lastname: Deramecourt
authors.forename: Marie-Anne
authors.initials: MA
authors.lastname: Mackowiak-Cordoliani
authors.forename: Ronald S
authors.initials: RS
authors.lastname: Black
authors.forename: Rodolphe
authors.initials: R
authors.lastname: Lavielle
authors.forename: André
authors.initials: A
authors.lastname: Delacourte
authors.forename: Florence
authors.initials: F
authors.lastname: Pasquier
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000097:blood / Q000276:immunology* / Q000517:prevention & control; D023582:Alzheimer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D016229:Amyloid beta-Peptides / Q000276:immunology* / Q000378:metabolism; D001921:Brain / Q000378:metabolism / Q000473:pathology; D017809:Fatal Outcome; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D020961:Lewy Body Disease / Q000276:immunology* / Q000378:metabolism
chemical_list: D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D007074:Immunoglobulin G; D007075:Immunoglobulin M